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Background: Although many patients with facial paralysis have obtained benefits or completely recovered after
acupuncture or electroacupuncture therapy, it is still difficult to list intuitive evidence besides evaluation using
neurological function scales and a few electrophysiologic data. Hence, the aim of this study is to use more intuitive
and reliable detection techniques such as facial nerve magnetic resonance imaging (MRI), nerve electromyography,
and F waves to observe changes in the anatomic morphology of facial nerves and nerve conduction before and
after applying acupuncture or electroacupuncture, and to verify their effectiveness by combining neurological
function scales.
Methods/Design: A total of 132 patients with Bell’s palsy (grades III and IV in the House-Brackmann [HB] Facial
Nerve Grading System) will be randomly divided into electroacupuncture, manual acupuncture, non-acupuncture,
and medicine control groups. All the patients will be given electroacupuncture treatment after the acute period,
except for patients in the medicine control group. The acupuncture or electroacupuncture treatments will be
performed every 2 days until the patients recover or withdraw from the study. The primary outcome is analysis
based on facial nerve functional scales (HB scale and Sunnybrook facial grading system), and the secondary
outcome is analysis based on MRI, nerve electromyography and F-wave detection. All the patients will undergo MRI
within 3 days after Bell’s palsy onset for observation of the signal intensity and facial nerve swelling of the
unaffected and affected sides. They will also undergo facial nerve electromyography and F-wave detection within 1
week after onset of Bell’s palsy. Nerve function will be evaluated using the HB scale and Sunnybrook facial grading
system at each hospital visit for treatment until the end of the study. The MRI, nerve electromyography, and F-wave
detection will be performed again at 1 month after the onset of Bell’s palsy.
Trial registration: Chinese Clinical Trials Register identifier: ChiCTR-IPR-14005730. Registered on 23 December 2014.
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Acupuncture therapy is widely used for the treatment of
Bell’s palsy in China and throughout the world [1–4];
however, its effectiveness is still debatable because con-
clusions drawn from Cochrane reviews [5, 6] and meta-
analyses [7, 8] do not support its clinical application,
whereas clinical trials tend to prove its efficacy [9, 10].
Except for some defects in the protocol design and im-
plementation, different manipulations among Chinese* Correspondence: shenweidong1018@163.com
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article, unless otherwise stated.and foreign physicians, and the lack of powerful evi-
dence of objective detection and assessment besides the
neurological function scale, are very important reasons
for the conflicting opinions.
The detectable pathological changes of peripheral fa-
cial paralysis (including Bell’s palsy) are facial nerve
edema and bioelectric conduction disorders. The former
can be detected and evaluated using magnetic resonance
imaging (MRI) [11–15], the latter using more sensitive
neural electrophysiological methods [16].
Treatments for Bell’s palsy should differ according to
the stage of the disease [17], and the most important fac-
tor in treatment is not the kind of manipulation butdistributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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start in the acute stage within 7 days of palsy onset
[18–20]. Currently, electroacupuncture is widely used
in the treatment of Bell’s palsy, although there is inad-
equate evidence-based support, especially for use in the
acute stage. On the one hand, some clinical experiences
have revealed that an early and appropriate electroacu-
puncture therapy shortens the disease course and im-
proves the curative effect [9, 21]. On the other hand,
there are beliefs that electroacupuncture stimulation is
not appropriate for patients in the acute stage of Bell’s
palsy and that it is more likely to aggravate facial nerve
edema and bioelectric conduction disorders. Thus, the
efficacy of electroacupuncture for treating Bell’s palsy
starting from the acute stage is yet to be investigated.
The purpose of this study is to investigate the effects
of electroacupuncture therapy starting from the acute
stage of Bell’s palsy. Symptom improvements will be
evaluated by using the internationally accepted House-
Brackmann (HB) Facial Nerve Grading System and the
Sunnybrook facial grading system. Changes in facial
nerve edema and nerve conduction will be analyzed by
using MRI and neural electrophysiology techniques. TheFig. 1 Flowchart of the study. ENoP neural electrophysiologicalaim of the study is to provide a more reliable scientific
basis for evaluating the effectiveness of electroacupunc-
ture therapy for Bell’s palsy by combining clinical symp-
toms with physiology and electrophysiology findings.
Methods/Design
Study design
The present study is a randomized controlled clinical
study (see Fig. 1).
Ethics
The trial will be carried out in accordance with the Dec-
laration of Helsinki. Written informed consent will be
obtained from each participant. This study is approved
by the Medical Ethics Committee Board of Baoshan In-
tegrated Traditional Chinese Medicine and Western
Medicine Hospital of Shanghai (2014XBN02).
Patients
Both outpatients and inpatients in the departments of
acupuncture, neurology, and gerontology of Baoshan In-
tegrated Traditional Chinese Medicine and Western
Medicine Hospital of Shanghai, China, are being selected
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from 18 to 60 years old are being enrolled. All the patients
are being randomized into group A (electroacupuncture
in the acute stage), group B (manual acupuncture in the
acute stage), group C (non-acupuncture in the acute
stage), or group D (medicine control group).
Sample size calculation
Count data of the parallel controlled trial (1:1) will be
analyzed statistically using a two-sided superiority test
where α = 0.05, power = 90 %. The formula used for cal-
culation is as follows:
n ¼ Z1−a þ Z1−β
 2  σ21 þ σ22
 
δ2
It is assumed that the change in the standard deviation
of the Sunnybrook facial grading system score before
and after the treatment in the control group is 10 points
and that that in the treatment group is 18 points. A
change will be considered clinically significant if the
change of Sunnybrook scale score before and after the
treatment in the treatment group is 13 points higher
than that in the control group. The estimated sample
size is arrived at as follows:
n ¼ Z1−a þ Z1−β
 2  σ21 þ σ22
 
δ2
¼ 1:96þ 1:28ð Þ
2  102 þ 182ð Þ
132
≈26:33
It is assumed that the change in the standard deviation
of HB scale score before and after the treatment in the
control group is 1 point and that that in the treatment
group is 3 points. A change will be considered clinically
significant if the change of HB scale score before and
after the treatment in the treatment group is 2 points
higher than that in the control group. The estimated
sample size is arrived at as follows:
n ¼ Z1−a þ Z1−β
 2  σ21 þ σ22
 
δ2
¼ 1:96þ 1:28ð Þ
2  12 þ 32ð Þ
22
¼ 26
It is determined that there should be at least 27 pa-
tients in each group. The dropout rate is considered to
be 20 %, and thus at least 33 patients should be enrolled
in each group. Hence, a total of 132 patients are re-
quired to conduct this study.
Inclusion criteria
Patients with Bell’s palsy who meet the following inclu-
sion criteria will be enrolled in the study: unilateral facial
paralysis; age between 18 and 60 years; Bell’s palsy onsetwithin 2 days; HB scale score above grade III; normal
superficial and deep sensations, muscle strength and
muscle tension in limbs, with negative pathological
signs; and absence of heart failure, abnormal liver func-
tion, and other severe complications of diabetes mellitus.
Exclusion criteria
Patients meeting any of the following criteria will be ex-
cluded from the study: pregnancy or breastfeeding;
woman of childbearing age who is unwilling to use con-
traceptives during the study period; patients who re-
ceived medicine or acupuncture therapy in other
hospitals before this study; diabetes course ≥5 years,
grade 3 hypertension ≥3 years, and hyperlipidemia ≥3
years; history of malignant tumor, sexually transmitted
disease, renal or hepatic disease, gastric or duodenal
ulcer, glaucoma, acute otitis, ipsilateral chronic otitis, tu-
berculosis, immunodeficiency syndromes, recent head
injury, psychiatric disease, infectious disease, or any
other condition that puts the person at risk of being in-
fluenced by the study treatment or that may affect the
completion of the study; and participation in other clin-
ical trials within 3 months.
Elimination criteria
Patients with cerebral infarction, cerebral hemorrhage,
or other brain tumors diagnosed on the basis of skull
computed tomography or MRI and patients who refuse
to sign the written informed consent or did not coordin-
ate with the randomized enrollment will be excluded
from the study.
Randomization
Patients will be randomly assigned to one of the four
treatment groups. Computerized randomization will be
performed by an investigator who has no direct contact
with the participants. The assessors will be blinded to
the group allocation. The investigator performing the
acupuncture intervention will not be intrinsically
blinded; however, the investigator will not be allowed to
communicate with the participants or the assessors
about the treatment procedures and outcomes. A sealed
envelope containing an allocation sequence number for
each patient will be opened right after each patient is
verified to meet the eligibility criteria and has signed the
informed consent form. If any error or disclosure with
regard to randomization occurs, a new randomization
sequence will be generated starting from the problematic
serial number and applied to subsequent patients.
Interventions
Acupuncture therapy
Acupuncture will be performed by specialists in trad-
itional Chinese medicine, and the protocol will follow
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in Clinical Trials for Acupuncture 2010 checklist [22,
23], as shown in Table 1.
Acute stage
Patients in groups A and B will receive acupuncture ther-
apy at the Cuanzhu (BL2), Yangbai (GB14), Sizhukong
(TE23), Qianzheng, Yingxiang (LI20), Quanliao (SI18),
Dicang (ST4), Hegu (LI4), and Taichong (LR3) points. The
acupuncture points are identified according to the method
of point location issued by the World Health Organization
(WHO). The acupuncture needles will be inserted
straightly or obliquely with a depth of 10–30 mm to bring
about the desired sensation of deqi (see Table 2), and the
needles will be left in place for 20 minutes. The acupunc-
ture therapy will be performed once every 2 days. Accord-
ingly, patients in group A (electroacupuncture in the
acute stage) will receive electroacupuncture therapy at the
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comYingxiang (LI20), and Qianzheng-Dicang (ST4) points
(2 Hz, density wave, 20 minutes) once every 2 days. Pa-
tients in group C will not receive acupuncture therapy.
Stable and recovery stages
Patients in groups A–C will receive straight or oblique
acupuncture with a depth of 10–30 mm at the Cuanzhu
(BL2), Yangbai (GB14), Sizhukong (TE23), Qianzheng,
Yingxiang (LI20), Quanliao (SI18), Dicang (ST4), Hegu
(LI4), and Taichong (LR3) points (identified according to
the method of point location issued by the WHO) to
bring out the desired sensation of deqi from the eighth
day after palsy onset. The needles will be retained for 20
minutes. The electroacupuncture will be performed
once every 2 days. Accordingly, patients in groups A–C
will receive electroacupuncture therapy at the Yangbai
(GB14)-Sizhukong (TE23), Quanliao (SI18)-Yingxiang
(LI20), and Qianzheng-Dicang (ST4) points (2 Hz,
density wave, 20 minutes). All patients will be givencription
itional Chinese medicine
puncture has been historically used to treat facial palsy. Additionally,
known to be a safe treatment used in a wide range of symptoms
ed by Bell’s palsy
subjects of the intervention group all receive the same acupuncture
lectroacupuncture treatment
4, TE23, Qianzheng, LI20, SI18, ST4 (unilateral, affected side), LI4, LR3
teral)
30 mm (exact depth shown in Table 2)
i
e in electric stimulation, others in manual stimulation (exact details are
e text)
inutes
mm (diameter) × 25 mm (length) disposal needle (Huatuo Acupuncture,
ou, China)
ssions/wk for 4 wk
other interventions
ubjects are informed that they will receive acupuncture or
troacupuncture treatment, which can potentially reduce Bell’s palsy
ptoms; however, the non-acupuncture control group would have to
plete the evaluations during the first week before receiving the same
tment as the acupuncture group.
cialists in traditional Chinese medicine with at least 3 years of practice
cupuncture
-acupuncture control is used as a control because sham acupuncture
not be a substituted for a physiologically inert placebo, and Western
icine is recommended in the guideline.
Western medicine control group forms a positive control and
pletes the evaluations during the first week after randomization.
Table 2 Acupuncture points and needle insertion procedures
Acupuncture point Direction Depth (mm)
GB14 (yangbai, affected side) Transversely toward geisoma 20–30
SJ23 (sizhukong, affected side) Obliquely toward partes temporalis 20–30
Qianzheng (extra point, affected side) Perpendicular to the skin 20–30
LI20 (yingxiang, affected side) Obliquely along nasolabial sulcus toward the root of the nose 20–30
SI18 (quanliao, affected side) Perpendicular to the skin 20–30
ST4 (dicang, affected side) Transversely toward ST6 10–20
LI4 (hegu, bilateral) Perpendicular to the skin 20–30
LR3 (taichong, bilateral) Perpendicular to the skin 20–30
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study withdrawal.
Western medicine treatment
Patients in each group will be given oral administration
of prednisone (30 mg once daily for 5 days and then 5
mg daily until study withdrawal), mecobalamin (0.5 mg
thrice daily), and fursutiamine (50 mg thrice daily) until
complete recovery. Group D serves as the medicine con-
trol group, which will not be given any acupuncture or
electroacupuncture therapy throughout the trial.
Outcome
To reduce the outcome assessment bias, the investiga-
tors will be given specific training for facial grading, and
both the Sunnybrook and HB scales will be used for out-
come evaluation.
Primary outcome
Evaluation will be performed using facial paralysis evalu-
ation scale (HB and Sunnybrook scales). Measurements
will be performed at the above-mentioned time points
and at the first month after therapy by three physicians,
and the averaged value will be recorded. Meanwhile, the
time for the first change in the score after the start of
treatment will be labeled. The period from palsy onset
to the first change in the facial paralysis evaluation scale
score and the patient’s overall recovery period will be re-
corded, and comparison between the interventional
groups and the control group will be conducted.
Secondary outcomes
MRI examinations
The MRI examinations (MAGNETOM version 3.0T
MRI Scanner using head matrix coils; Siemens Medical
Solutions, Erlangen, Germany) will be performed within
7 days and at 1 month after the onset of Bell’s palsy. The
conventional MRI protocol for this study consists of the
following sequences. Three-dimensional constructive
interference in the steady state will be performed in an
axial orientation with the following parameters: 18-cmfield of view (FOV), repetition time/echo time (TR/TE)
of 8.58/3.91 ms, 64 sections of 0.5-mm thickness, with a
matrix of 320×320 pixels, flip angle 50 degrees, band-
width of 460 Hz, and acquisition time of 6 minutes, 12
seconds. A volume-interpolated body examination will
be performed in precontrast and contrast T1 with the
following parameters: 18-cm FOV, TR/TE of 20/3.69 ms,
32 sections of 1-mm thickness, with a matrix of
320×320 pixels, flip angle 12 degrees, bandwidth of 130
Hz, and acquisition time of 3 minutes, 4 seconds.
Gadolinium-diethylenetriamine pentaacetic acid (con-
trast medium) will be administered intravenously at a
dosage of 0.1 mmol/kg.
Facial nerve electromyography
The surface recording electrodes will be placed on the
orbicularis oculi muscle and the orbicularis oris. The ref-
erence electrode will be placed on the nasal bone. The
ground electrode will be placed on one arm. Super
strong stimulations will be applied to the stylomastoid
foramen, and the latency and amplitude of the motor
evoked potentials (M wave) at the initial location will be
observed, first on the unaffected side and then at the
same location on the affected side. The results of the
two sides will be compared. Meanwhile, the R1/M-wave
ratio in latency will be measured. The measurements
will be performed within 7 days and at 1 month after
palsy onset.
F-wave detection of facial nerve
The participants will be in supine position in a silent
room with constant temperature, and the examination
(normally right side first) will be performed after 5 mi-
nutes of relaxation. An electromyogram evoked potential
test (Dantec Keypoint; Alpine Biomed, Skovlunde,
Denmark) will be performed. The surface electrodes will
be placed on the orbicularis oculi muscle and the de-
pressor anguli oris muscle, and the stimulus (20 times of
square wave with a time history of 0.3 ms, firing fre-
quency of 1 Hz) will be applied on nervi auriculares
anteriores. After the stimulating current strength is
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filtering range of approximately 100–5000 Hz and ana-
lysis duration of 50 ms, the presence of F waves in the
affected and unaffected sides and the relevant data will
be recorded. The measurements will be performed
within 7 days and at 1 month after palsy onset.
Statistical analysis
In this study, statistical analyses of data will be per-
formed by professionals rather than investigators using
intention-to-treat and per-protocol approaches. All
demographic and clinical characteristics of the subjects
(such as sex, age) will be processed based on descriptive
analyses. Quantitative data will be presented as average,
standard deviation, median value, and range. Qualitative
data will be presented as the frequency and percentage.
For the primary outcome measurements, a repeated-
measures multifactorial analysis will be performed to
identify differences between groups (differences within
each group based on time, and the effects of the inter-
action of the variables based on group) to compare the
differences in HB and Sunnybrook score changes be-
tween the interventional and control groups based on
time (baseline, every treatment time and 1 month after
palsy onset). The period from the onset to the first
change in facial paralysis evaluation scale score in and
the patients’ overall recovery period will be compared
using one-way analysis of variance (ANOVA) between
all groups. For the secondary outcome measurements, a
χ2 test will be used to compare the edema onset fre-
quency of the facial nerve on the affected side. One-way
ANOVA will be applied to identify differences in results
of facial nerve electromyography and F-wave detection
between groups. In cases of non-normally distributed
data, the Kruskal-Wallis H test will be performed.
All adverse events reported during the study will be
included in the clinical report, and the prevalence of ad-
verse events will then be calculated. The percentage of
participants with adverse events in each group will be
calculated and compared using the χ2 test or Fisher’s
exact test. Statistical analyses will be performed using
IBM SPSS for Windows version 19.0 statistical software
(IBM, Armonk, NY, USA). All the tests will be two-
sided, and a P value <0.05 will be considered statistically
significant.
Discussion
It is recognized that prednisolone but not antiviral medi-
cine shows significant short- and long-term positive
treatment effects in patients with Bell’s palsy [24–29].
This treatment should be used routinely for patients
with Bell’s palsy and should be considered in all of these
patients irrespective of degree of palsy [30]. It is noticed
in clinics that acupuncture therapy alone is not likely toachieve significant curative effect without prednisolone
for patients with HB scale scores equal to or over grade
V. So, prednisolone is given to treat Bell’s palsy conven-
tionally nowadays.
This study is designed based on a treatment including
giving prednisolone, which will be used in every group.
The purpose is to compare the different results of inter-
vention by electroacupuncture, acupuncture, and non-
acupuncture in the acute stage, followed by electroacu-
puncture in subsequent stages. Thus, the protocol is
more likely to be in accord with current clinical practice
and to be more conducive to protecting patients’ rights,
as well as avoiding delay in treatment owing to bias of
study design to a maximum extent. Hence, it is more
scientific and reasonable to adopt a treatment strategy of
Western medicine plus acupuncture therapy or electroa-
cupuncture in the acute stage of Bell’s palsy facial
paralysis.
The greatest uncertainty in this study is the effect of
acupuncture or electroacupuncture on duration of dis-
ease or the completeness of ultimate recovery. However,
either positive or negative effects eventually will be used
to illustrate the facts, facilitating development of a rea-
sonable clinical strategy in the future.
The aim of this study is to provide evidence of the ef-
fects of electroacupuncture therapy on Bell’s palsy. The
sample size estimation of the present study was based
on previous clinical scale evaluation, and the obtained
sample size might, to some extent, differ from previous
electrophysiological studies owing to the difficulty in
obtaining data regarding the latter, such as mean values
of a healthy population and patients with Bell’s palsy.
This may be one of the aspects affecting the ultimate
data analysis of the present study. Hence, it might be ne-
cessary to expand the sample size during the study to
obtain credible results.
Trial status
Recruitment started in January 2015 and will be com-
pleted by the end of May 2017.
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